Immunicum AB News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

10.11.17	Immunicum AB (publ) and Academic Collaborators Publish Preclinical Ilixadencel Mode of Action Data in Journal Oncoimmunology (GlobeNewswire)
07.11.17	Immunicum AB (publ) Presents Further Preclinical Ilixadencel Mode of Action Data at Annual SITC Meeting (GlobeNewswire)
02.11.17	Notice to Attend the Extraordinary General Meeting of Immunicum (GlobeNewswire)
02.11.17	The Board of Directors of Immunicum AB (publ) Resolves on a 90% Secured Rights Issue of up to SEK 223 Million to Finance Further Development of its Portfolio (GlobeNewswire)
10.10.17	Immunicum AB (publ) Announces Appointment of Sharon Longhurst as Head of CMC (GlobeNewswire)
09.10.17	Immunicum AB (publ) Announces the Nomination Committee for AGM 2018 (GlobeNewswire)
28.09.17	Immunicum AB (publ) Announces Completion of HCC Phase I/II Clinical Study (GlobeNewswire)
21.09.17	Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's Mode of Action at the SITC Meeting in the US (GlobeNewswire)
22.08.17	Immunicum AB (publ) Announces Upcoming Presentations at Conferences in August and September (GlobeNewswire)
18.08.17	Immunicum AB (publ): Interim Report Q2 - Corporate Update and Outlook (GlobeNewswire)
17.08.17	Immunicum AB (publ) Completes Strategic Analysis and Defines Updated Clinical Development Plan for Ilixadencel (GlobeNewswire)
15.08.17	Immunicum AB (publ) Announces Last Patient Last Visit in the Ongoing Phase I/II Hepatocellular Carcinoma Study (GlobeNewswire)
10.08.17	Immunicum AB (publ) Announces Enrollment of First United States Patient in the Ongoing Phase 2 MERECA Trial for Ilixadencel (GlobeNewswire)
13.12.16	Immunicum AB announces FDA clearance of its Investigational New Drug application for INTUVAX in metastatic renal cell carcinoma (GlobeNewswire)
22.11.16	Immunicums valberedning för årsstämman 2017 utsedd (GlobeNewswire)
18.11.16	Immunicum: Quarterly report July 2016 - September 2016 (GlobeNewswire)
14.11.16	Immunicum AB presented poster at SITC conference on INTUVAX HCC I/II clinical study - announces last patient included in study extension (GlobeNewswire)
26.10.16	Immunicum AB: Kommuniké från årsstämma i Immunicum AB (publ) den 26 oktober 2016 (GlobeNewswire)
26.10.16	Immunicum AB: Report from the Annual General Meeting of Immunicum AB (publ) on October 26, 2016 (GlobeNewswire)
25.08.16	Immunicum: Steven Glazer, Charlotte Edenius and Kerstin Valinder Strinnholm proposed as new Board members (GlobeNewswire)
26.07.16	Immunicum announces that a patent application in China regarding the Company's CD70-technology will be granted (GlobeNewswire)
22.07.16	Immunicum submits IND application to the Food and Drug Administration (FDA) for approval to treat kidney cancer patients in the United States in its ongoing phase II-trial (GlobeNewswire)
22.07.16	Immunicum AB Announces Appointment of Chief Medical Officer, Peter Suenaert, M.D., Ph.D. (GlobeNewswire)
23.06.16	Immunicum Announces Preliminary Plans to Initiate Clinical Trials with INTUVAX in Melanoma in both Sweden and the U.S. (GlobeNewswire)
21.06.16	Immunicum raises approximately SEK 128 million in oversubscribed rights issue - exercises over-allotment option (GlobeNewswire)
13.06.16	Immunicum presents continued improvement in phase I/II survival data for INTUVAX-treated renal cancer patients (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Immunicum AB

Aktien Top/Flop

Meistgelesene Nachrichten